{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:25:38Z","timestamp":1789676738855,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Roche Spain","award":["ML40361"],"award-info":[{"award-number":["ML40361"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40271-020-00454-3","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T06:02:47Z","timestamp":1601013767000},"page":"241-248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["High-Efficacy Disease-Modifying Therapies in People with Relapsing\u2013Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9858-3555","authenticated-orcid":false,"given":"Jorge","family":"Maurino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Sotoca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel P.","family":"Sempere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Brieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"L\u00f3pez de Silanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana B.","family":"Caminero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Terzaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Gracia-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Saposnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"issue":"1","key":"454_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","volume":"26","author":"R Dobson","year":"2019","unstructured":"Dobson R, Giovannoni G. Multiple sclerosis\u2014a review. Eur J Neurol. 2019;26(1):27\u201340.","journal-title":"Eur J Neurol"},{"key":"454_CR2","doi-asserted-by":"publisher","first-page":"102343","DOI":"10.1016\/j.msard.2020.102343","volume":"45","author":"ST Timmermans","year":"2020","unstructured":"Timmermans ST, de Groot V, Beckerman H. Ten-year disease progression in multiple sclerosis: walking declines more rapidly than arm and hand function. Mult Scler Relat Disord. 2020;45:102343.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"454_CR3","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s12889-019-6907-x","volume":"19","author":"JM Garc\u00eda-Dom\u00ednguez","year":"2019","unstructured":"Garc\u00eda-Dom\u00ednguez JM, Maurino J, Mart\u00ednez-Gin\u00e9s ML, et al. Economic burden of multiple sclerosis in a population with low physical disability. BMC Public Health. 2019;19(1):609.","journal-title":"BMC Public Health"},{"key":"454_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09395-w","author":"H Li","year":"2019","unstructured":"Li H, Hu F, Zhang Y, Li K. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. J Neurol. 2019. https:\/\/doi.org\/10.1007\/s00415-019-09395-w(Online ahead of print).","journal-title":"J Neurol"},{"key":"454_CR5","doi-asserted-by":"publisher","first-page":"e636","DOI":"10.1212\/NXI.0000000000000636","volume":"7","author":"JM Stankiewicz","year":"2019","unstructured":"Stankiewicz JM, Weiner HL. An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2019;7:e636.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"454_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.msard.2019.06.036","volume":"35","author":"RC Lucchetta","year":"2019","unstructured":"Lucchetta RC, Leonart LP, Becker J, Pontarolo R, Fernandez-Llim\u00f3s F, Wiens A. Safety outcomes of disease-modifying therapies for relapsing-remitting multiple sclerosis: a network meta-analysis. Mult Scler Relat Disord. 2019;35:7\u201315.","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"454_CR7","doi-asserted-by":"publisher","first-page":"v","DOI":"10.7224\/1537-2073.2018-098","volume":"20","author":"C Heesen","year":"2018","unstructured":"Heesen C, Rahn AC. Shared decision making in managing multiple sclerosis: revisiting the research agenda. Int J MS Care. 2018;20(6):v\u2013vi.","journal-title":"Int J MS Care"},{"key":"454_CR8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.msard.2018.11.016","volume":"27","author":"I Eskyte","year":"2019","unstructured":"Eskyte I, Manzano A, Pepper G, Pavitt S, Ford H, Bekker H, Chataway J, Schmierer K, Meads D, Webb E, Potrata B. Understanding treatment decisions from the perspective of people with relapsing remitting multiple sclerosis: a critical interpretive synthesis. Mult Scler Relat Disord. 2019;27:370\u20137.","journal-title":"Mult Scler Relat Disord"},{"key":"454_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/hex.13093","author":"J Desborough","year":"2020","unstructured":"Desborough J, Brunoro C, Parkinson A, et al. \u2018It struck at the heart of who I thought I was\u2019: a meta-synthesis of the qualitative literature examining the experiences of people with multiple sclerosis. Health Expect. 2020. https:\/\/doi.org\/10.1111\/hex.13093.","journal-title":"Health Expect."},{"key":"454_CR10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1146\/annurev-publhealth-031912-114353","volume":"34","author":"T Rice","year":"2013","unstructured":"Rice T. The behavioral economics of health and health care. Annu Rev Public Health. 2013;34:431\u201347.","journal-title":"Annu Rev Public Health"},{"key":"454_CR11","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.3389\/fpsyg.2019.01490","volume":"10","author":"A D\u00edaz","year":"2019","unstructured":"D\u00edaz A, Esparcia C. Assessing risk aversion from the investor\u2019s point of view. Front Psychol. 2019;10:1490.","journal-title":"Front Psychol"},{"issue":"3","key":"454_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.jpainsymman.2019.06.013","volume":"58","author":"M Wilski","year":"2019","unstructured":"Wilski M, Kocur P, Gorny M, Koper M, Nadolska A, Chmielewski B, Tomczak M. Perceptions of multiple sclerosis impact and treatment efficacy beliefs: mediating effect of patient\u2019s illness and self-appraisals. J Pain Symptom Manag. 2019;58(3):437\u201344.","journal-title":"J Pain Symptom Manag"},{"key":"454_CR13","doi-asserted-by":"publisher","first-page":"102354","DOI":"10.1016\/j.msard.2020.102354","volume":"45","author":"G Saposnik","year":"2020","unstructured":"Saposnik G, Sotoca J, Sempere AP, et al. Therapeutic status quo in patients with relapsing-remitting multiple sclerosis: a sign of poor self-perception of their clinical status? Mult Scler Relat Disord. 2020;45:102354 (published online ahead of print, 2020 Jul 2).","journal-title":"Mult Scler Relat Disord"},{"key":"454_CR14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fneur.2018.00174","volume":"9","author":"G Saposnik","year":"2018","unstructured":"Saposnik G, Montalban X. Therapeutic inertia in the new landscape of multiple sclerosis care. Front Neurol. 2018;9:174.","journal-title":"Front Neurol"},{"issue":"2","key":"454_CR15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292\u2013302.","journal-title":"Ann Neurol"},{"issue":"11","key":"454_CR16","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444\u201352.","journal-title":"Neurology"},{"issue":"40","key":"454_CR17","doi-asserted-by":"publisher","first-page":"12574","DOI":"10.1523\/JNEUROSCI.2614-09.2009","volume":"29","author":"GI Christopoulos","year":"2009","unstructured":"Christopoulos GI, Tobler PN, Bossaerts P, Dolan RJ, Schultz W. Neural correlates of value, risk, and risk aversion contributing to decision making under risk. J Neurosci. 2009;29(40):12574\u201383.","journal-title":"J Neurosci"},{"issue":"2","key":"454_CR18","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1152\/jn.00853.2009","volume":"103","author":"I Levy","year":"2010","unstructured":"Levy I, Snell J, Nelson AJ, Rustichini A, Glimcher PW. Neural representation of subjective value under risk and ambiguity. J Neurophysiol. 2010;103(2):1036\u201347.","journal-title":"J Neurophysiol"},{"issue":"3","key":"454_CR19","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/j.1542-4774.2011.01015.x","volume":"9","author":"T Dohmen","year":"2011","unstructured":"Dohmen T, Falk A, Huffman D, Sunde U, Schupp J, Wagner GG. Individual risk attitudes: measurement, determinants, and behavioral consequences. J Eur Econ Assoc. 2011;9(3):522\u201350.","journal-title":"J Eur Econ Assoc"},{"key":"454_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12883-016-0577-4","volume":"16","author":"G Saposnik","year":"2016","unstructured":"Saposnik G, Sempere AP, Roulas R, Prefasi D, Selchen D, Maurino J. Decision making under uncertainty, therapeutic inertia, and physicians\u2019 risk preferences in the management of multiple sclerosis (DIScUTIR MS). BMC Neurol. 2016;16:58.","journal-title":"BMC Neurol"},{"key":"454_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/23279095.2015.1125905","volume":"24","author":"R Green","year":"2017","unstructured":"Green R, Kalina J, Ford R, Pandey K, Kister I. SymptoMScreen: a tool for rapid assessment of symptom severity in MS across multiple domains. Appl Neuropsychol Adult. 2017;24:183\u20139.","journal-title":"Appl Neuropsychol Adult"},{"key":"454_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40120-020-00176-6","volume":"9","author":"J Meca-Lallana","year":"2020","unstructured":"Meca-Lallana J, Maurino J, Hern\u00e1ndez-P\u00e9rez MA, Sempere AP, Brieva L, Garc\u00eda-Arcelay E, Terzaghi M, Saposnik G, Ballesteros J. Psychometric properties of the SymptoMScreen questionnaire in a mild disability population of patients with relapsing-remitting multiple sclerosis: quantifying the patient\u2019s perspective. Neurol Ther. 2020;9:173\u20139.","journal-title":"Neurol Ther"},{"issue":"5","key":"454_CR23","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1177\/1352458517690821","volume":"23","author":"RH Benedict","year":"2017","unstructured":"Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler. 2017;23(5):721\u201333.","journal-title":"Mult Scler"},{"issue":"2","key":"454_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F. ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96\u2013120.","journal-title":"Mult Scler"},{"key":"454_CR25","first-page":"65","volume":"8","author":"G Saposnik","year":"2017","unstructured":"Saposnik G, Sempere AP, Prefasi D, Selchen D, Ruff CC, Maurino J, Tobler PN. Decision-making in multiple sclerosis: the role of aversion to ambiguity for therapeutic inertia among neurologists (DIScUTIR MS). Front Neurol. 2017;8:65.","journal-title":"Front Neurol"},{"key":"454_CR26","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000487329","volume":"87","author":"J Nielsen","year":"2018","unstructured":"Nielsen J, Saliger J, Montag C, Markett S, N\u00f6hring C, Karbe H. Facing the unknown: fear of progression could be a relevant psychological risk factor for depressive mood states among patients with multiple sclerosis. Psychother Psychosom. 2018;87:190\u20132.","journal-title":"Psychother Psychosom"},{"issue":"1\u20132","key":"454_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jns.2013.02.018","volume":"331","author":"C Heesen","year":"2013","unstructured":"Heesen C, K\u00f6pke S, Solari A, Geiger F, Kasper J. Patient autonomy in multiple sclerosis-possible goals and assessment strategies. J Neurol Sci. 2013;331(1\u20132):2\u20139.","journal-title":"J Neurol Sci"},{"key":"454_CR28","doi-asserted-by":"publisher","first-page":"03007","DOI":"10.1051\/shsconf\/20185103007","volume":"51","author":"M Pranka","year":"2018","unstructured":"Pranka M. Biographical disruption and factors facilitating overcoming it. SHS Web Conf. 2018;51:03007.","journal-title":"SHS Web Conf"},{"issue":"12","key":"454_CR29","doi-asserted-by":"publisher","first-page":"e82796","DOI":"10.1371\/journal.pone.0082796","volume":"8","author":"C Tur","year":"2013","unstructured":"Tur C, Tintor\u00e9 M, Vidal-Jordana \u00c1, Bichuetti D, Nieto-Gonz\u00e1lez P, Ar\u00e9valo MJ, Arrambide G, Anglada E, Gal\u00e1n I, Castillo J, Nos C, Rio J, Mart\u00edn MI, Comabella M, Sastre-Garriga J, Montalban X. Risk acceptance in multiple sclerosis patients on natalizumab treatment. PLoS ONE. 2013;8(12):e82796.","journal-title":"PLoS ONE"},{"key":"454_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jns.2017.03.001","volume":"376","author":"C Heesen","year":"2017","unstructured":"Heesen C, Kleiter I, Meuth SG, Kr\u00e4mer J, Kasper J, K\u00f6pke S, Gaissmaier W. Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients. J Neurol Sci. 2017;376:181\u201390.","journal-title":"J Neurol Sci"},{"key":"454_CR31","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.msard.2015.03.003","volume":"4","author":"RJ Fox","year":"2015","unstructured":"Fox RJ, Salter A, Alster JM, et al. Risk tolerance to MS therapies: survey results from the NARCOMS registry. Mult Scler Relat Disord. 2015;4:241\u20139.","journal-title":"Mult Scler Relat Disord"},{"issue":"14","key":"454_CR32","doi-asserted-by":"publisher","first-page":"e1634","DOI":"10.1212\/WNL.0000000000007245","volume":"92","author":"RJ Fox","year":"2019","unstructured":"Fox RJ, Cosenza C, Cripps L, Ford P, Mercer M, Natarajan S, Salter A, Tyry T, Cofield SS. A survey of risk tolerance to multiple sclerosis therapies. Neurology. 2019;92(14):e1634\u201342.","journal-title":"Neurology"},{"key":"454_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1749-6632.2011.06200.x","volume":"1235","author":"R Mata","year":"2011","unstructured":"Mata R, Josef AK, Samanez-Larkin GR, Hertwig R. Age differences in risky choice: a meta-analysis. Ann N Y Acad Sci. 2011;1235:18\u201329.","journal-title":"Ann N Y Acad Sci"},{"key":"454_CR34","doi-asserted-by":"publisher","first-page":"102046","DOI":"10.1016\/j.msard.2020.102046","volume":"41","author":"J Maurino","year":"2020","unstructured":"Maurino J, Mart\u00ednez-Gin\u00e9s ML, Garc\u00eda-Dom\u00ednguez JM, et al. Workplace difficulties, health-related quality of life, and perception of stigma from the perspective of patients with multiple sclerosis. Mult Scler Relat Disord. 2020;41:102046.","journal-title":"Mult Scler Relat Disord"},{"key":"454_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-020-00429-4","author":"EJD Webb","year":"2020","unstructured":"Webb EJD, Meads D, Eskyt\u0117 I, et al. The impact of reproductive issues on preferences of women with relapsing multiple sclerosis for disease-modifying treatments. Patient. 2020. https:\/\/doi.org\/10.1007\/s40271-020-00429-4.","journal-title":"Patient"},{"key":"454_CR36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2147\/NDT.S17522","volume":"7","author":"NJ Kachuck","year":"2011","unstructured":"Kachuck NJ. When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis. Neuropsychiatr Dis Treat. 2011;7:197\u2013208.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"454_CR37","doi-asserted-by":"publisher","first-page":"e0174858","DOI":"10.1371\/journal.pone.0174858","volume":"12","author":"J Kr\u00e4mer","year":"2017","unstructured":"Kr\u00e4mer J, Tenberge JG, Kleiter I, et al. Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis? PLoS One. 2017;12(4):e0174858.","journal-title":"PLoS One"},{"issue":"2","key":"454_CR38","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.neuron.2018.03.019","volume":"98","author":"WH Jung","year":"2018","unstructured":"Jung WH, Lee S, Lerman C, Kable JW. Amygdala functional and structural connectivity predicts individual risk tolerance. Neuron. 2018;98(2):394\u2013404.","journal-title":"Neuron"},{"issue":"1","key":"454_CR39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40271-018-0326-4","volume":"12","author":"C Vass","year":"2019","unstructured":"Vass C, Rigby D, Payne K. \u201cI was trying to do the maths\u201d: exploring the impact of risk communication in discrete choice experiments. Patient. 2019;12(1):113\u201323.","journal-title":"Patient"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-020-00454-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-020-00454-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-020-00454-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T23:21:41Z","timestamp":1632525701000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-020-00454-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["454"],"URL":"https:\/\/doi.org\/10.1007\/s40271-020-00454-3","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]},"assertion":[{"value":"5 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by the Medical Department of Roche Farma Spain (ML40361). The funding source had no role in the design, analysis, and interpretation of the data, review or approval of the manuscript, and decision to submit for publication. Ocrelizumab (manufactured by Roche Farma) was not included as a therapeutic option for any of the simulated case scenarios.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JM is an employee of Roche Farma Spain. GS reports receiving grants and personal fees from Roche Canada and Spain and being supported by the Heart and Stroke Foundation of Canada Scientist Award. JS, APS, LB, CLS, ABC, MT, and JGG declare they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was approved by the institutional review board of the Hospital Universitari Cl\u00ednic i Provincial de Barcelona (code ML40361).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Written informed consent to participate in the study was obtained from all subjects.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Qualified researchers may request access to individual patient-level data through the clinical study data request platform (). Further details on Roche\u2019s criteria for eligible studies are available at . For further details on Roche\u2019s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see .","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"JM: concept and design, interpretation of data, and drafting the manuscript and revising it for intellectual content. JS: data acquisition, interpretation of data, and revising manuscript for intellectual content. APS: design of the case scenarios, interpretation of data, and revising manuscript for intellectual content. LB, CLS, ABC, and JGG: data acquisition, interpretation of data, and revising manuscript for intellectual content. MT: interpretation of data and revising manuscript for intellectual content. GS: concept and design, statistical analysis, interpretation of data, and drafting the manuscript and revising it for intellectual content.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}